KDC-MN-124 – Kodiac biolabs

Plain-language summaryIntrigue 65 / 100

P21 is a synthetic peptide derived from ciliary neurotrophic factor (CNTF) developed for neuroprotection and neurogenesis. Used in research for memory and Alzheimer disease investigations. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundSingle-lab provenance

45/100

Mechanistically coherent neurogenic peptide stuck behind a single-lab evidence wall

Look, P21 has one thing going for it that cerebrolysin itself never could: it’s an actual molecule. Seven amino acids, defined sequence, definable dose. When Khalid Iqbal’s group at the New York State Institute for Basic Research pulled this peptide out of the active fraction and pinned it to a CNTF-receptor-related mechanism driving dentate gyrus neurogenesis, that was genuinely useful work. Adult hippocampal neurogenesis is a serious research target, and having a defined peptide that demonstrably stimulates it in rodent models is not nothing.

The mechanism is what we find most interesting here. CNTF receptor signaling in the context of adult neurogenesis is a real frontier. P21 appears to operate through pathways related to the CNTF receptor complex, producing dose-dependent increases in new neuron formation in the dentate gyrus and corresponding improvements in spatial learning and memory in aged and AD-model rodents. That’s a coherent story. It’s not a trivial “more BDNF” hand-wave; theres a specific receptor angle with specific behavioral readouts, and the ciliary neurotrophic factor pathway is mechanistically distinct from the BDNF/TrkB axis that most neurogenic compounds lean on.

Here’s the problem: it’s still basically one group, one lab. Iqbal’s work on P21 spans several papers and the lab has real credibility in the AD field, but external replication is thin. We haven’t seen multi-lab confirmation of the neurogenesis effect or independent validation of the CNTF-receptor mechanism at scale. The animal models are relevant — transgenic AD mice and cognitively aging rodents are the right system for these claims — but rodent-to-human translation in neurogenesis research has historically been brutal. The dentate gyrus neurogenesis story itself is contested in humans in ways it simply isn’t in rodents.

There’s also no human data. None. No phase 1, no small-N pilot, not even a case series. For a compound with this much mechanistic specificity, thats a notable gap. Pharmacokinetics in humans are essentially unknown, and we dont know whether intranasal or subcutaneous administration delivers meaningful CNS levels in a primate brain at any practical dose.

What P21 does offer is genuine bench utility as a CNTF-pathway probe for investigators working in adult neurogenesis or AD-related cognitive biology. If you’re running hippocampal slice work or transgenic rodent behavioral studies, P21 is a more tractable tool than cerebrolysin’s poorly-defined mixture. That’s real value, just narrow. We think this sits as a solid single-lab story worth watching but not worth centering a program on until someone outside the Iqbal consortium picks it up and replicates the core findings independently.

Novelty: 55
Mechanism promise: 58
In-category differentiation: 48
Evidence quality: 28
Translational signal: 30
Research bench value: 42

Rationale P21 earns real marks for its defined CNTF-receptor mechanism and dentate gyrus neurogenesis signal in AD rodent models, but the evidence base is almost entirely Iqbal’s group at NY State IBR with no meaningful external replication and zero human data; single-lab preclinical only holds the overall to 45.

CNTF-derived neurogenic peptide

A short peptide derived from a cerebrolysin fraction with documented hippocampal neurogenesis activity in animal models.

Abstract

P21 is a peptide of the sequence Ala-Asp-Asn-Phe-Val-Phe-Lys derived from the active fraction of cerebrolysin (or related neurotrophic preparations) and identified by Khalid Iqbal’s group at the New York State Institute for Basic Research. The compound stimulates neurogenesis in the dentate gyrus through a CNTF-receptor-related mechanism, producing dose-dependent improvements in spatial learning and memory in rodent models of cognitive aging and Alzheimer disease pathology. The compound has not been advanced to human clinical trials. Pharmacokinetics are poorly characterized in humans. The compound is sold as a research peptide; investigational doses parallel cerebrolysin range scaled to peptide content.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-124Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-124

P21 (Cerebrolysin-derived peptide)

Abstract

Read the full monograph